Travis Mickle’s work developing better drugs for attention deficit hyperactivity disorder is deeply personal – he has ADHD and so do his children. After receiving his PhD in organic chemistry from the University of Iowa, Mickle went on to work at New River Pharmaceuticals, where he developed the leading treatment for ADHD, Vyvanse. Now he […]
Pharmaceuticals
Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017
After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]
Oral drug delivery startup raises $39m for robotic pill
San Jose, Calif.-based Rani Therapeutics has some seriously big-name backers: Alphabet (NSDQ:GOOGL), Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN) have all invested in the startup. This month, the company raised $38.7 million as part of a $126.5 million offering of equity and options or warrants, according to an SEC filing. So far, 12 investors have contributed to the offering. Rani […]
Adherium launches next-gen monitor for AstraZeneca’s Turbuhaler
Adherium Ltd. (ASK:ADR) said today that it launched a next-gen version of its SmartTurbo adherence monitor for AstraZeneca‘s (NYSE:AZN) Turbuhaler. The company’s monitor features usability improvements to make the device’s installation and removal easier for older patients with COPD. It also includes larger buttons to help patients access features like audio and visual reminders, battery monitoring […]
Sanofi’s Toujeo beats Lantus at stabilizing blood sugar in T2D patients
Adults with Type II diabetes treated with Sanofi‘s (NYSE:SNY) Toujeo Gla-300 insulin glargine had better blood glucose stability than those treated with the company’s Lantus Gla-100 insulin glargine product, according to a study presented at the annual meeting of the European Association for the Study of Diabetes. The analysis re-analyzed patient data from the Edition […]
Insulet touts real-world data for Omnipod insulin management tech
Insulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes. The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data […]
FDA to review re-submitted application for Sorrento’s lidocaine patch
Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that the FDA has received the resubmitted version of a new drug application for its lidocaine patch, ZTlido. The San Diego, Calif.-based company is developing the drug-device product for the relief of pain associated with post-herpetic neuralgia. The FDA said it is slated to finish reviewing the company’s NDA by […]
VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon
Medtronic (NYSE:MDT) touted data for its In.Pact Admiral drug-coated balloon this week at the Vascular Interventional Advances (VIVA) 2017 conference. The company presented two-year, real-world data from the In.Pact Global study, as well as four-year results from the pivotal In.Pact SFA study. Data from the In.Pact Global study showed a 83.3% rate of freedom from clinically-driven target […]
Press release: Raumedic presents customized pharma solutions
(Press release) – For the first time after several years, Raumedic will be present at the pharma trade show CPhI Worldwide in Frankfurt, Germany. From October 24 to 26, the company will be showcasing a wide range of polymer products and components to professionals from the pharmaceutical industry, including drug delivery systems as well as […]
Novartis partners with nonprofit for novel malaria drug
David Hughes and his team at Novartis (NYSE:NVS) have screened nearly a million compounds to find a few to specifically target the drug-resistant plasmodium parasite that causes malaria. This technique – of throwing hundreds of thousands of drugs through a variety of high-throughput tests and hoping to find the ones that perform well – is common […]